Case Reports in Infectious Diseases
Volume 2018 (2018), Article ID 6549496, 9 pages
https://doi.org/10.1155/2018/6549496

Case Report

Listeria monocytogenes Brain Abscess: Controversial Issues for the Treatment—Two Cases and Literature Review

Beatrice Tiri,¹ Giulia Priante,¹ Lavinia Maria Saraca,¹ Lucia Assunta Martella,² Stefano Cappanera,² and Daniela Francisci¹

¹Infectious Diseases Clinic, Department of Medicine, University of Perugia, Perugia, Italy
²Infectious Diseases Clinic, Department of Medicine, “S. Maria” Hospital, Terni, Italy

Correspondence should be addressed to Beatrice Tiri; tiri.beatrice@gmail.com

Received 12 March 2018; Revised 11 June 2018; Accepted 8 July 2018; Published 24 July 2018

Academic Editor: Tomoyuki Shibata

Copyright © 2018 Beatrice Tiri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Listeria monocytogenes (LM) is an opportunistic pathogen, and the most common central nervous system manifestation is meningitis while listerial brain abscesses are rare. We describe 2 cases of brain abscess due to LM and a literature review. Only 73 cases were reported in the literature from 1968 to 2017. The mean age was 51.9, and the mortality rate was 27.3%. In 19% of cases, no risk factors for neurolisteriosis were identified. Blood cultures were positive in 79.5% while CSF or brain abscess biopsy material was positive in 50.8%. In 40% was started a monotherapy regimen while in 60% a combination therapy without substantial differences in mortality. Fifty-two percent underwent neurosurgery while 45.3% has been treated only with medical therapy. The mortality rates were, respectively, 13% and 38.2%. Only 25% of patients who were treated for ≤6 weeks underwent neurosurgery, while 80% of those who were treated for ≥8 weeks were operated. The mortality rates were, respectively, 12.5% and 0%, suggesting that a combined approach of surgery and prolonged medical therapy would have an impact on mortality. We believe that it is essential to carry out this review as brain abscesses are rare, and there are no definitive indications on the optimal management, type, and duration of therapy.

1. Introduction

Listeria monocytogenes (LM) is a facultative intracellular Gram-positive bacillus, widely distributed in nature and therefore found in multiple ecological sites, which can cause listeriosis, a serious foodborne bacterial infection [1]. Invasive listeriosis is classified into three forms: bacteraemia, neurolisteriosis, and maternal-neonatal infection. The incidence of listeriosis in the western hemisphere is estimated to be approximately three to six cases per 1 million population per year [2]. Epidemiological studies have identified host risk factors for bacteraemia and neurolisteriosis which include old age, innate and cellular immune deficiencies, cancer, HIV infection, cirrhosis, diabetes mellitus, alcoholism, and immunosuppressive therapies [3–6]. The most common central nervous system manifestation is meningitidis, while meningoencephalitis, rhombencephalitis, and cerebritis are less common [7]. Brain abscesses are extremely rare as they account for approximately 1–10% of CNS listerial infections and are observed in 1% of all listerial infections [8]. There are unresolved issues regarding surgical drainage of the abscess, selection of antibiotic regimen, and optimal treatment duration. We describe two cases (the first without evident immunodeficiency and the second affected by bullous pemphigoid) of brain abscess due to Listeria monocytogenes and discuss them by reviewing the literature on this topic.

2. Case Report

2.1. Case 1

A 62-year-old immunocompetent man with no significant previous medical history was hospitalized for high-grade fever, intractable hiccup, and interscapular pain. On admission, his white blood cell count was 11 × 10⁹/L (normal range 4.50–10.80 10³ mmc), his C-reactive protein (CRP) was elevated at 4.30 mg/dl (normal range 0.00–0.75 mg/dl), while his chest radiograph, abdomen ultrasound, and echocardiography were normal. A computed tomography (CT) scan of the brain revealed a diffuse abnormal pattern (presence of aspecific inflammatory material) with hypodense lesions located in the trigonum of lateral ventricle in an underlying condition of demyelination and gliosis, suspicious for chronic ischemic vascular disease. A broad-spectrum antibiotic therapy with vancomycin and ceftriaxone was initiated. The patient became afebrile within a few days. A neurological examination found him to be alert and oriented, and he did not have a stiff neck. However, the patient had persistent hiccups and headache. Magnetic resonance imaging (MRI) showed enhancement of both trigeminal nerves and white spot lesions on the pons, cerebral peduncle, midbrain, and thalamus. He was then transferred to the Neurology Department where a lumbar puncture was carried out. His cerebrospinal fluid (CSF) was clear, WBC count was 50 cells/µl, 100% lymphocytes, normal glucose level (normal range 40–70 mg/dl), 103 mg/dl protein (normal range 15–45 mg/dl), and the CSF culture was negative. As a viral etiology was suspected, antibiotic therapy with vancomycin + ceftriaxone was discontinued and treatment with acyclovir and steroid was initiated. After 72 hours, a progressive deterioration of his clinical-neurological condition occurred: he became hyperpyretic and aphasic and Glasgow Coma Score (GCS) was 9. CT brain imaging showed the involvement of the subcortical left temporoparietal lobe, and he was then transferred to the Infectious Disease Department. Blood cultures were performed, and another lumbar puncture was carried out. A cerebrospinal fluid (CSF) analysis showed cloudy CSF with increased spinal column pressure, granulocytic pleocytosis (180 cells/µl, with PMN 90%), normoglychorrachia, and 145 mg/dl spinal fluid protein. A combination antimicrobial therapy with ampicillin 3 g/6 h + gentamicin 80 mg/8 h was initiated; 72 hours later, fever and other systemic signs and symptoms disappeared resulting in complete recovery (GCS15). Listeria monocytogenes were isolated from the patient’s blood and recognized from CSF using the molecular technique (Multiplex Real-Time PCR Meningitis/Encephalitis Filmarray bioMerieux). The patient was treated with intravenous ampicillin for 4 weeks, with combination intravenous gentamicin for the initial 2 weeks and switched to oral trimethoprim/sulfamethoxazole 160/800 mg/8 h for 1 month. An MRI was repeated after 8 weeks of antibiotic therapy due to the persistence of fluent aphasia. MR imaging showed a ring-enhancing lesion in the left fronto-temporoparietal lobe, consistent with a brain abscess with significant perilesional edema (Figure 1). Surgical excision of the lesion was performed. Molecular identification of the pus using polymerase chain reaction (PCR) identified DNA of Listeria monocytogenes. The patient was represcribed intravenous ampicillin + gentamicin for 4 weeks, and therapy was then switched to oral trimethoprim/sulfamethoxazole 160/800 mg/12 h for further 4 weeks. Patient’s condition has improved progressively and with a complete recovery of linguistic abilities.

Figure 1: MR image showing the evolution of the ring-enhancing lesion in the left fronto-temporoparietal lobe in a brain abscess with significant perilesional edema.

2.2. Case 2

A 72-year-old man with a history of bullous pemphigoid treated with a monoclonal antibody was admitted to another hospital due to a balance disorder. A neurological examination identified a left hemiplegia with no sensory deficits. An immediate CT brain scan showed a ring-enhancing cortical-subcortical lesion on the right frontal-parietal hemisphere. In view of the CT scan findings, gadolinium MRI of the brain was performed. MRI showed a caudal extension of the lesion with irregular enhancement and a necrotic region (Figure 2). Blood cultures were collected before initiating antimicrobial therapy. A few days later, his blood cultures grew Listeria monocytogenes. Based on organism sensitivity, intravenous therapy with ampicillin 3 g/6 h + gentamicin 80 mg/8 h + vancomycin 1 g/12 h was initiated. Steroid therapy was also administered due to the associated moderate mass effect. The patient was then transferred to our Infectious Diseases Department for further workup and management. Forty-eight hours after the initiation of target therapy, the patient was afebrile. Twenty days later, he showed progressive clinical and neurologic deterioration characterized by visual hallucinations, frontal symptoms with disinhibition, and persistent hemiplegia. An MRI brain scan showed a substantial increase in lesion size, and new lesions appeared on splenium of corpus callosum and right temporal lobe with a significant mass effect on the right lateral ventricle. Trimethoprim/sulfamethoxazole 160/800 mg/8 h was added. The patient underwent a surgical biopsy of the lesion. Molecular identification of the brain tissue using PCR identified Listeria monocytogenes DNA. At the follow-up appointment five weeks later, additional imaging studies were performed which showed a considerable reduction in the size and enhancement of the lesions. Ampicillin, gentamicin, and vancomycin therapy was stopped while trimethoprim/sulfamethoxazole therapy was continued. The patient’s neurological condition improved. An MRI brain scan performed after 8 weeks of antibiotic therapy, showed significant improvement, with noticeable decrease in the amount of vasogenic edema. Trimethoprim/sulfamethoxazole therapy was discontinued, and the patient was discharged. A year after the listeria brain abscess diagnosis, the patient does not show any significant neurologic deficits and is able to carry out all activities of daily living.

(a)

(b)

Figure 2: MR image showing a caudal extension of the lesion with irregular enhancement with irregular enhancement and a necrotic region (FLAIR/long TR).

3. Discussion

Listeria monocytogenes can invade tissues that are normally resistant to infection, such as the CNS, a gravid uterus, or a fetus. This bacterium reaches the CNS due to hematogenous spread from the gastrointestinal tract [9]. The epithelium of the choroid plexus enables LM to gain access to CNS and causes a meningitides infection. On the other hand, LM may reach the brain parenchyma via the cerebral capillary endothelium, a single layer of brain microvascular endothelial cells characterized by tight junctions. It has been reported that LM-infected macrophages may pass through endothelial cells via the middle cerebral artery resulting in cerebritis which leads to brain abscess formation [10–13].

Furthermore, LM can use a peripheral intraneural route to invade the CNS. A recent animal study suggests that once the bacteria have gained access to the CNS via the peripheral nervous system, the infection can spread along the axons, producing additional lesions by traveling within the axons of the trigeminal nerve [14–16]. According to Bojanowski et al., once inside the CNS, the bacterium may travel along the white fiber tracts of the brain, resulting in a distinct anatomical imaging thus enabling early diagnosis [17]. The spreading of multiple listeria brain abscess within the cerebral nervous system through the intrassonal pathway justified their specific pattern and why they have more detrimental effects than bacterial brain abscess. In our case 1, MRI shows that the spreading follows the arcuate fasciculus. In case 2, the caudal extension of the lesions may also suggest that the lesion follows the projection fiber tracts.

Brain abscesses are extremely rare, accounting for approximately 1–10% of CNS listerial infections. These abscesses are generally located in the subcortical grey matter, especially in the thalamus and basal ganglia [18, 19]. Protection against LM is predominantly cell-mediated. Individuals with impaired cell-mediated immunity are at risk of developing listerial infections [20].

To the best of our knowledge, only 73 cases of brain abscess caused by L. monocytogenes were reported in the literature between 1968 and 2017. We report further two cases (Table 1) [1, 13, 17, 21–23].

Table 1: Seventy-three cases of brain abscess caused by Listeria monocytogenes reported in the literature between 1968 and 2017 (we described two other cases).

N.
Age/sex
Underlying diseases
Blood
CSF/brain abscess
Surgery/type
Antibiotic
Duration of therapy
Outcome
References

1
70/M
Myasthenia gravis in immunosuppressive TP
+
−
ND
Ampicillin + gentamicin; trimethoprim/sulfamethoxazole
6 weeks ampicillin + gentamicin for 10 days trimethoprim/ sulfamethoxazole
Survived
Chalouhi et al., 2013

2
57/F
Cirrhosis; DM
+
+
Biopsy
Ampicillin + gentamicin
NR
Died
Matera et al., 2012

3
60/M
DM; rheumatoid arthritis methotrexate
−
+
ND
(a) Amoxicillin + trimethoprim/sulfamethoxazole
(b) Trimethoprim/sulfamethoxazole
(c) Linezolid
(d) Amoxicillin
(a) 17 days
(b) 20 days
(c) 33 days
(d) NR
Survived
Coste et al., 2012

4
52/M
OLT in HCC secondary to hepatitis C and alcoholic cirrhosis; cyclosporine
+
+
Craniotomy with resection of the lesion
Ampicillin + gentamicin + penicillin G
3 weeks (gentamicin only for 2 weeks)
Survived
Choudhury et al., 2013

5
56/F
Primary biliary cirrhosis; OLT; tacrolimus, azathioprine, prednisone
+
+
Biopsy
Ampicillin + gentamicin
8 weeks (gentamicin only for 2 weeks)
Survived
Tseng et al., 2013

6
42/M
None
+
+
Biopsy and drainage
Ampicillin + gentamicin + meropenem
NR
Survived
Beynon et al., 2013

7
47/F
SLE; mycophenolate
−
+
ND
Ampicillin
6 weeks
Survived
Horta-Baas et al., 2013

8
16/F
SLE; mycophenolate
+
−
External ventricles device
Trimethoprim/sulfamethoxazole + ampicillin + meropenem
13 weeks trimethoprim/sulfamethoxazole; ampicillin for 4 weeks; meropenem for 5 weeks (total of 22 weeks)
Survived
Perini et al., 2014

9
81/M
Myelodys plastic syndrome; basal cell skin carcinoma, prostate cancer treated
+
+
Craniotomy with resection of the lesion
Ampicillin
NR
Survived
West et al., 2015

10
52/F
DM, hypothyroidism, prednisolone, azathioprine
+
−
Biopsy
Ampicillin + gentamicin
6 weeks
Survived
Al-HarabI et al., 2015

11
81/F
DM
NR
+
Biopsy
Ampicillin
8 weeks
Survived
Dejesus-Alvelo et al., 2015

12
74/F
DM
+
NR
NR
Vancomycin + ampicillin + ceftriaxone
NR
Survived
Bojanowski et al. [17]

13
32/F
LAC
+
NR
NR
Ampicillin + trimethoprim/sulfamethoxazole + linezolid
8 weeks; linezolid for 10 days
Survived
Fervienza et al., 2016

14
72/M
None
−
+
ND
Ampicillin
NR
Survived
Mano et al., 2017

15
52/M
Inflammatory myositis treated with prednisolone and azathioprine
+
−
ND
Ampicillin
6 weeks
Survived
Onder et al., 2016

16
70/M
Alcoholism
+
+
ND
Ampicillin + gentamicin + vancomycin
3–6 weeks
Died
Cone et al. [13]

17
56/M
AIDS
+
−
ND
Ampicillin + gentamicin
Article not available
Survived
Patey et al., 1989

18
49/M
Rheumatic fever, alcoholism, DM
+
−
ND
Penicillin G + streptomycin + tetracycline
NR
Died
Buchner and Schneierson, 1968

19
64/M
DM, aortic valve replacement
+
−
ND
Ampicillin + gentamicin
4 weeks + ampicillin for 2 weeks
Survived
Soto and Sliman, 1992

20
71/M
DM, rheumatic heart disease
+
−
ND
Ampicillin + gentamicin
NR
Died
Eckburg et al. [22]

21
56/M
AIDS
+
−
ND
Ampicillin + gentamicin
Article not available
Survived
Patey et al., 1989

22
70/F
Cirrhosis, DM, heart failure
+
ND
ND
Ampicillin + trimethoprim/sulfamethoxazole
Article not available
Died
Sivalinga et al., 1992

23
25/F
Ulcerative colitis
NR
NR
ND
NR
NR
Died
Larsson and Linell, 1979

24
87/M
None
+
+
ND
Penicillin G + chloramphenicol
NR
Died
Spilkin et al., 1968

25
63/M
None
+
−
ND
Ampicillin
NR
Died
Kennard et al., 1979

26
24/M
None
+
−
ND
Ampicillin + gentamicin
6 weeks, gentamicin only for 10 days
Survived
Smiatacz et al., 2006

27
53/F
None
+
−
ND
Minocycline, gentamicin
2 weeks
Survived
Mrowka et al., 2002

28
63/F
None
−
−
ND
NR
NR
Died
Brun-Buisson et al., 1985

29
43/F
None
−
−
ND
Ampicillin
NR
Died
Brun-Buisson et al., 1985

30
39/M
None
NR
−
ND
NR
NR
Died
Kwantes and Isaac, 1971

31
54/F
None
NR
NR
ND
NR
NR
Died
Larsson and Linell, 1979

32
1+1/4/M
None
NR
NR
ND
Amoxicillin
Article not available
Survived
Mancini et al., 1990

33
70/M
NONE
−
+
Craniectomy and open biopsy
Ampicillin
NR
Survived
Salgado et al., 1996

34
53/M
Cirrhosis, seizure
+
−
+
Penicillin G + erythtomycin
Article not available
Survived
Halkin et al., 1971

35
85/M
DM
+
−
+
Ampicillin
Article not available
Died
Brown et al., 1991

36
43/M
OSAS, alcoholism
+
−
+
NR
Article not available
Survived
Douen and Bourque, 1997

37
0/M
Pronatis
+
−
+
Ampicillin + gentamicin
Article not available
Survived
Banerji and Noya, 1999

38
63/M
MM
+
−
Biopsy
(a) Ampicillin
(a) 5 weeks
Survived
Leiti et al. [20]

(b) Linezolid + rifampin
(b) 15 weeks

39
61/M
DM
NR
NR
Biopsy
Trimethoprim/sulfamethoxazole + chloramphenicol
3 weeks, trimethoprim/sulfamethoxazole alone for 20 weeks
Survived
Sjostrom et al., 1995

40
60/M
HIV
NR
+
Craniotomy and intraoperative cultures
Penicillin G + chloramphenicol
NR
Died
Harris et al., 1989

41
68/M
Leukemia
NR
NR
ND
Chloramphenicol
NR
Died
Larsson et al., 1978

42
NR/M
None
NR
NR
ND
NR
NR
Died
Pollock et al., 1984

43
2/M
NR
NR
+
Craniotomy with resection of the lesion
NR
NR
Survived
Umenai et al., 1978

44
49/M
Renal transplant
+
+
ND
Chloramphenicol
NR
Died
Crocker and Leicester, 1976

45
16/M
ALL
+
+
ND
Penicillin G + chloramphenicol
NR
Survived
Dykes et al., 1979

46
20/M
ALL
+
+
ND
Ampicillin + chloramphenicol + erythromycin, gentamicin
8 weeks
Survived
Hutchinson and Heyn, 1983

47
6/F
ALL
+
+
ND
Ampicillin, vancomycin, netilmicin
NR
Survived
Viscoli et al., 1991

48
46/F
Ulcerative colitis
+
+
ND
Ampicillin, gentamicin
8 weeks, 4 weeks
Survived
Soares-Fernandes et al., 2008

49
58/F
SLE
+
−
ND
Penicillin G + tobramycin
ARTICLE NOT AVAILABLE
Survived
Takano et al., 1999

50
58/F
Immunoblastic lymphadenopathy
+
−
ND
Ampicillin
8 weeks
Survived
Maezawa et al. [21]

51
65/M
DM
+
NR
ND
Ampicillin + gentamicin
4 weeks
Died
Wu et al., 2010

52
19/M
Juvenile rheumatoid arthritis, tetralogy of Fallot
NR
+
ND
Vancomycin + ampicillin
Article not available
Survived
Turner et al., 1995

53
55/M
Renal transplant
+
−
+
Ampicillin
Article not available
Survived
Lechtenberg et al., 1979

54
45/M
Renal transplant
+
−
Craniotomy and drainage
Ampicillin
10 weeks
Survived
Stam et al., 1982

55
60/F
Rheumatoid arthritis
+
−
Biopsy
Ampicillin, amoxicillin
8 weeks, 24 months
Survived
Updike et al., 1990

56
66/F
AML, Crohn’s disease
+
+
Biopsy
Ampicillin
4 weeks
Survived
Eckburg et al. [22]

57
47/M
AIDS
+
−
Craniotomy
Ampicillin, gentamicin, vancomycin
NR
Died
Cone et al. [13]

58
54/F
Sarcoidosis
+
−
Biopsy
Ampicillin + gentamicin
NR
Died
Ackermann et al., 2001

59
23/F
ITP
+
−
Drainage of the abscess
Trimethoprim/sulfamethoxazole
12 months
Survived
Treebupachatsaul et al., 2006

60
58/M
MM
+
−
Craniotomy and drainage
(a) Trimethoprim/sulfamethoxazole + gentamicin (b) Trimethoprim/sulfamethoxazole
(a) 12 weeks (gentamicin only 2 weeks) (b) 5 months
Survived
Al-Khatti and Al- Tawfiq, 2010

61
55/M
Glioblastoma multiforme
−
+
Biopsy
Amoxicillin + gentamicin
12 weeks
Survived
Ganiere et al., 2006

62
51/M
Cardiac transplant
+
+
Stereotactic brain aspiration
Ampicillin + gentamicin
6 weeks, gentamicin only 2 weeks
Survived
Eckburg et al. [22]

63
37/M
Cardiac transplant
+
+
Craniotomy with resection of the lesion
penicillin G
8 weeks
NR
Eckburg et al. [22]

64
56/F
Primary biliary cirrhosis
+
+
Biopsy
Ampicillin + gentamicin
6 weeks gentamicin only 2 weeks
Survived
Cone et al. [13]

65
50/M
Sarcoidosis
−
+
Craniotomy
Trimethoprim/sulfamethoxazole
Article not available
Survived
Poropatich and Phillips, 1992

66
51/F
Crohn’s disease
−
+
Biopsy
Ampicillin + gentamicin
12 weeks (gentamicin not reported)
Survived
Stefanovich et al., 2010

67
50/M
Cardiac transplant, DM
−
+
Biopsy and aspiration
Ampicillin + gentamicin
18 weeks of ampicillin; 14 weeks gentamicin
Survived
Eckburg et al. [22]

68
75/M
None
−
ND
+
Ampicillin + gentamicin
Article not available
Survived
Mylonakis et al., 1998

69
77/M
CLL
−
NR
+
Chloramphenicol
Article not available
NR
Cleveland and Gelfand, 1993

70
58/M
CLL
−
+
Biopsy
Ampicillin + gentamicin
6 weeks
Survived
Dee and Lorber, 1986

71
Child
ALL
NR
NR
+
NR
Article not available
Survived
Antunes et al., 1998

72
68/F
Breast cancer
+
ND
Biopsy
Ampicillin, amoxicillin
10 weeks, 24 weeks
Survived
Limmahakhun and Chayakulkeeree [1]

73
47/F
Evans syndrome, SLE, DM
+
−
ND
Ampicillin, amoxicillin
6 weeks, NR
Survived
Limmahakhun and Chayakulkeeree [1]

Case 1
62/M
None
+
+
Craniotomy with resection of the lesion
(a) Ampicillin + gentamicin (b) Trimethoprim/sulfamethoxazole
(a) 8 weeks (gentamicin only 4 weeks) (b) 8 weeks
Survived

Case 2
72/M
Bullous pemphigoid
+
+
Biopsy
(a) Ampicillin + gentamicin + trimethoprim/sulfamethoxazole (b) Trimethoprim/sulfamethoxazole
(a) 5 weeks (b) 3 weeks
Survived

Forty-eight of these patients were male (64%). The mean age of the patients was 51.9, and median age was 55 years (range 0–87 years). Fifty-nine out of 73 had one or more risk factors described in the literature for the development of neurolisteriosis (81%), 15/75 had no risk factors (19%), and in 1 case, nothing was specified. The mortality rate was 27.3%.

Blood cultures were reported for 63 cases: 50/63 were positive (79.5%).

L. monocytogenes was isolated from the CSF or brain abscesses in 31/61 patients (50.8%).

The therapeutic regimen was reported for 67/75 cases, while it is unknown in 8/75.

Twenty-seven out of 67 patients received a monotherapy regimen (40%), while a combination therapy was prescribed for 40/67 (60%) cases: a two-drug therapy was prescribed in 31 cases (50.8%) and a three-drug therapy was administered in 9 cases (14.7%).

The mortality rate in the monotherapy regimen group was 18.5% (five patients out of 27) while the group that received combination therapy showed a 20% mortality rate (eight patients out of 40). Fifty-nine out of 67 patients received a beta-lactam regimen, while 8/59 received a free beta-lactam regimen.

Considering the substantial numerical difference of the two samples, these are not comparable.

Ampicillin was the most commonly prescribed antibiotic as it was administered to 49 patients: in 21 patients, it was prescribed as monotherapy; in 23 cases, it was administered in combination with gentamicin; in 3 cases, it was administered in combination with trimethoprim/sulfamethoxazole while in 2 cases, it was administered in combination with other drugs such as vancomycin or macrolides.

There are currently no guidelines for brain abscess management. Starting from the 2010 consensus on the management and treatment of brain abscesses, we reviewed our case series [24].

Thirty-nine out of 75 patients underwent neurosurgery (52%). Four out of 31 died (13%). Thirty-four patients out of 75 (45.3%) had only been treated with medical therapy. Of these, 15/34 died (38.2%). In 2 cases, no data have been reported.

Therefore, in our case series, taking into account all of the possible bias, mortality would appear to be significantly higher in the group of patients treated exclusively with medical therapy.

In our opinion, this is a very interesting finding which requires further investigation.

However, as yet, there is no evidence concerning the appropriate duration of therapy for those patients who underwent neurosurgery.

According to a recent consensus study, antimicrobial treatment for brain abscesses should generally last 6–8 weeks and treatment for those undergoing neurosurgery should last 4–6 weeks [24].

From our literature review, the duration of therapy was known in 36/75 patients. Sixteen out of 36 received less than or equal to 6 weeks while 20/36 patients were treated for 8 weeks or more. Of the group of patients who received ≤6 weeks of therapy, 4/16 (25%) underwent neurosurgery, while of those belonging to the group who received ≥8 weeks, 16/20 (80%) underwent neurosurgery.

A 12.5% mortality rate was observed for the first group while 0% died in the second group, thus suggesting that a combination of surgery and prolonged medical therapy has a positive impact on mortality.

We believe that it is essential to carry out this review as brain abscesses are rare, and there are no definitive guidelines on the optimal management, type, and duration of therapy. LM infection should also be suspected in immunocompetent patients, and new molecular biology techniques play key roles in the early diagnosis of this rare pathology.

4. Conclusions

In our literature review, we found that listeria brain abscess is not related to advanced age and that it is related to high mortality (27.3%).

Diagnosis should not be suspected only in immunocompromised patients as it was found in 20% of patients who had no risk factor.

Blood cultures were positive in more than 80% of cases. Most patients received a beta-lactam regimen, and mortality appears to be lower in patients treated with combination regimens.

This result looks certainly very interesting and should be explored with dedicated studies (i.e., sharp difference in mortality between the group undergoing neurosurgery and the group that only received medical therapy). Furthermore, the specific pattern of brain diffusion, reported and highlighted in our two clinical cases, should be considered when this diagnosis is hypothesized.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

References

S. Limmahakhun and M. Chayakulkeeree, “Listeria monocytogenes brain abscess: two cases and review of the literature,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 44, no. 3, pp. 468–478, 2013.

P. Pagliano, T. Ascione, G. Boccia, F. De Caro, and S. Esposito, “Listeria monocytogenes meningitis in the elderly: epidemiological, clinical and therapeutic findings,” Le Infezioni in Medicina, vol. 24, no. 2, pp. 105–111, 2016.

C. M. De Noordhout, B. Devleesschauwer, F. J. Angulo et al., “The global burden of listeriosis: a systematic review and meta-analysis,” The Lancet Infectious Diseases, vol. 14, no. 11, pp. 1073–1082, 2014.

P. Pagliano, F. Arslan, and T. Ascione, “Epidemiology and treatment of the commonest form of listeriosis: meningitis and bacteraemia,” Le Infezioni in Medicina, vol. 25, no. 3, pp. 210–216, 2017.

C. Charlier, É. Perrodeau, A. Leclercq et al., “Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study,” The Lancet Infectious Diseases, vol. 17, no. 5, pp. 510–519, 2017.

J. A. Vázquez-Boland, M. Kuhn, P. Berche et al., “Listeria pathogenesis and molecular virulence determinants,” Clinical Microbiology Reviews, vol. 14, no. 3, pp. 584–640, 2001.

S. Morosi, D. Francisci, and F. Baldelli, “A case of rhombencephalitis caused by Listeria monocytogenes successfully treated with linezolid,” Journal of Infection, vol. 52, no. 3, pp. e73–e75, 2006.

B. Lorber, “Listeriosis,” Clinical Infectious Diseases, vol. 24, no. 1, pp. 1–11, 1997.

J. A. Vázquez-Boland, E. Krypotou, and M. Scortti, “Listeria placental infection,” mBio, vol. 8, no. 3, Article ID e00949-17, 2017.

O. Disson and M. Lecuit, “Targeting of the central nervous system by Listeria monocytogenes,” Virulence, vol. 3, no. 2, pp. 213–221, 2012.

D. A. Drevets and M. S. Bronze, “Listeria monocytogenes: epidemiology, human disease, and mechanisms of brain invasion,” FEMS Immunology & Medical Microbiology, vol. 53, no. 2, pp. 151–165, 2008.

D. Schlüter, S. Chahoud, H. Lassmann, A. Schumann, H. Hof, and M. Deckert-Schlüter, “Intracerebral targets and immunomodulation of murine Listeria monocytogenes meningoencephalitis,” Journal of Neuropathology and Experimental Neurology, vol. 55, no. 1, pp. 14–24, 1996.

L. A. Cone, M. M. Leung, R. G. Byrd, G. M. Annunziata, R. Y. Lam, and B. K. Herman, “Multiple cerebral abscesses because of Listeria monocytogenes: three case reports and a literature review of supratentorial listerial brain abscess(es),” Surgical Neurology, vol. 59, no. 4, pp. 320–328, 2003.

L. Dons, K. Weclewicz, Y. Jin, E. Bindseil, J. E. Olsen, and K. Kristensson, “Rat dorsal root ganglia neurons as a model for Listeria monocytogenes infections in culture,” Medical Microbiology and Immunology, vol. 188, no. 1, pp. 15–21, 1999.

C. Guldimann, B. Lejeune, S. Hofer et al., “Ruminant organotypic brain-slice cultures as a model for the investigation of CNS listeriosis,” International Journal of Experimental Pathology, vol. 93, no. 4, pp. 259–268, 2012.

A. Oevermann, S. Di Palma, M. G. Doherr, C. Abril, A. Zurbriggen, and M. Vandevelde, “Neuropathogenesis of naturally occurring encephalitis caused by Listeria monocytogenes in ruminants,” Brain Pathology, vol. 20, no. 2, pp. 378–390, 2010.

M. W. Bojanowski, R. Seizeur, K. Effendi, P. Bourgouin, E. Magro, and L. Letourneau-Guillon, “Spreading of multiple Listeria monocytogenes abscesses via central nervous system fiber tracts: case report,” Journal of Neurosurgery, vol. 123, no. 6, pp. 1593–1599, 2015.

R. Bartt, “Listeria and atypical presentations of Listeria in the central nervous system,” Seminars in Neurology, vol. 20, no. 3, pp. 361–373, 2000.

S. Matano, S. Satoh, Y. Harada, H. Nagata, and T. Sugimoto, “Antibiotic treatment for bacterial meningitis caused by Listeria monocytogenes in a patient with multiple myeloma,” Journal of Infection and Chemotherapy, vol. 16, no. 2, pp. 123–125, 2010.

O. Leiti, J. W. Gross, and C. U. Tuazon, “Treatment of brain abscess caused by Listeria monocytogenes in a patient with allergy to penicillin and trimethoprim-sulfamethoxazole,” Clinical Infectious Diseases, vol. 40, no. 6, pp. 907-908, 2005.

Y. Maezawa, A. Hirasawa, T. Abe et al., “Successful treatment of listerial brain abscess: a case report and literature review,” Internal Medicine, vol. 41, no. 11, pp. 1073–1078, 2002.

P. B. Eckburg, J. G. Montoya, and K. L. Vosti, “Brain abscess due to Listeria monocytogenes: five cases and a review of the literature,” Medicine, vol. 80, no. 4, pp. 223–235, 2001.

Y. Samra, M. Hertz, and G. Altmann, “Adult listeriosis–a review of 18 cases,” Postgraduate Medical Journal, vol. 60, no. 702, pp. 267–269, 1984.

M. Arlotti, P. Grossi, F. Pea et al., “Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses,” International Journal of Infectious Diseases, vol. 14, no. 4, pp. S79–S92, 2010.